Are you treating MASH patients and feeling overwhelmed by the ever-evolving landscape of treatment options? You're not alone. The American Association for the Study of Liver Diseases (AASLD) has just released crucial updated guidance on using semaglutide (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH), aiming to clarify patient selection, manage related health issues, and monitor treatment safety and effectiveness. Let's break down what this means for you and your patients.
On November 7, 2025, the AASLD published these updated recommendations in Hepatology, building upon their 2023 guidance on what was previously known as nonalcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD). Think of it as an essential upgrade to your clinical toolkit.
"This updated guidance reflects how quickly science and clinical practice are evolving and equips clinicians with the latest evidence and practical tools to manage MASLD and MASH," stated Dr. Grace Su, president of AASLD. "With therapies like semaglutide now available, patients and providers have new opportunities to improve liver health and overall wellness.” This highlights the optimism surrounding new treatment avenues for a disease that has long presented challenges.
Semaglutide earned its place as only the second FDA-approved MASH treatment on August 15, 2025. This accelerated approval stemmed from promising interim results from the phase 3 ESSENCE trial. The data showed that a weekly 2.4 mg subcutaneous injection over 72 weeks led to MASH resolution without worsening of fibrosis in a significant portion of patients (62.9% vs. 34.3% on placebo; P < .001). Furthermore, it also achieved at least a one-stage reduction in liver fibrosis without making the MASH worse (36.8% vs. 22.4% on placebo; P < .001). These numbers are compelling, suggesting real potential for improving patient outcomes. But here's where it gets controversial... some experts argue that relying solely on interim results for accelerated approval might be premature, emphasizing the need for long-term data to fully assess the drug's efficacy and safety.
To create these recommendations, a dedicated writing group, commissioned by the AASLD, meticulously analyzed data from the ESSENCE trial, focusing on both invasive (liver biopsy) and non-invasive tests (NITs) for liver fibrosis. Their goal? To pinpoint the right patients for semaglutide and effectively monitor their treatment response. They also delved into existing research on semaglutide regarding MASH and other FDA-approved uses, along with publicly available FDA documents and some unpublished data provided by Novo Nordisk.
The AASLD emphasizes that while the FDA prescribing information is the ultimate regulatory authority in the US, their guidance acts as a practical companion for clinicians. It's designed to help you confidently manage MASH patients who are good candidates for semaglutide.
Who Should Receive Semaglutide? Navigating Patient Selection
The guidance recommends semaglutide for patients with MASH and stage 2–3 fibrosis, diagnosed using NITs like VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), instead of relying solely on liver biopsy. For those with slightly elevated NIT results (VCTE 15-20 kPa, MRE 4.4-5 kPa, or ELF 10.5-11.3), the AASLD advises a case-by-case decision. This decision should be based on ruling out cirrhosis using another confirmatory NIT, cross-sectional imaging to check for liver contour abnormalities and signs of portal hypertension, or a platelet count below 150,000/mm3. And this is the part most people miss… Even though semaglutide is not yet approved for MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3 and/or evidence of portal hypertension), the AASLD suggests closely monitoring patients with compensated cirrhosis who are already taking semaglutide for another FDA-approved reason. This highlights the importance of careful observation and potential off-label use considerations.
Safety First: Key Considerations for Semaglutide Treatment
Reassuringly, the ESSENCE trial demonstrated a favorable hepatic safety profile for semaglutide, with no treatment discontinuations due to elevated liver enzymes. As a result, the updated guidance suggests routine hepatic panels only when clinically necessary. The most common side effects were gastrointestinal, such as nausea, diarrhea, constipation, and vomiting. However, these were generally mild and temporary. Patient education and gradual dose increases can greatly improve tolerance. Clinicians should also be vigilant for rare, but serious risks, including acute kidney injury, symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss.
Treatment Response and the Role of Combination Therapy
Lifestyle modifications remain the cornerstone of MASLD/MASH management, working hand-in-hand with semaglutide. Currently, combining semaglutide (at 2.4 mg/week) with resmetirom hasn't been studied. While no NITs can reliably predict histologic response in individual patients, the guidance suggests that reductions from baseline to 72 weeks in certain markers indicate significant improvement. These include ALT (greater than 17 U/L or a 20% reduction), CAP (a 30% or greater reduction), VCTE LSM (a 30% or greater reduction), MRE LSM (a 20% or greater reduction), and ELF (a 0.5 or greater reduction). Conversely, worsening ALT or NIT values may indicate a lack of response.
"This is an exciting time in the MASH field. With multiple FDA-approved therapies, AASLD is committed to leading the way in providing timely practical recommendations to clinicians on patient selection for treatment and monitoring for safety and efficacy," noted Dr. Meena Bansal.
Ultimately, this guidance represents a significant step forward in managing MASH. But, how comfortable are you relying on NITs instead of liver biopsies for patient selection? Do you agree with the AASLD's cautious approach to patients with compensated cirrhosis already on semaglutide for other conditions? Share your thoughts and experiences in the comments below – let's learn from each other!
